X4 Pharmaceuticals, Inc.
XFOR
$3.18
$0.3813.57%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 250.44% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 250.44% | -- | -- | -- | -- |
| Cost of Revenue | 21.64% | -- | -- | -- | -- |
| Gross Profit | 458.31% | -- | -- | -- | -- |
| SG&A Expenses | -28.25% | -13.85% | 52.56% | 92.55% | 30.13% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.15% | 2.58% | 47.42% | 28.83% | 33.54% |
| Operating Income | 22.61% | 74.68% | -41.73% | -26.77% | -31.36% |
| Income Before Tax | -128.29% | 100.61% | -107.17% | -1,509.52% | 263.12% |
| Income Tax Expenses | 105.56% | 78.95% | 681.82% | -42.31% | 20.00% |
| Earnings from Continuing Operations | -128.34% | 100.54% | -108.16% | -1,492.02% | 263.04% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -128.34% | 100.54% | -108.16% | -1,492.02% | 263.04% |
| EBIT | 22.61% | 74.68% | -41.73% | -26.77% | -31.36% |
| EBITDA | 23.22% | 75.91% | -41.00% | -26.27% | -31.25% |
| EPS Basic | -125.54% | 100.53% | -103.89% | -1,461.45% | 237.25% |
| Normalized Basic EPS | -63.73% | 100.60% | -102.91% | -1,478.61% | 78.61% |
| EPS Diluted | -125.59% | 100.51% | -103.07% | -1,461.45% | 237.00% |
| Normalized Diluted EPS | -64.03% | 100.59% | -102.91% | -1,478.61% | 78.65% |
| Average Basic Shares Outstanding | 10.95% | 2.60% | 2.10% | 1.97% | 18.79% |
| Average Diluted Shares Outstanding | 10.75% | 3.04% | 2.10% | 1.97% | 19.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |